Interim analysis of one year data from IVAN trial comparing ranibizumab and bevacizumab in wet AMD presented at conference

Source: National Institute for Health Research - Service, Delivery and Organisation programme
Area: News
The first year results from an NIHR Health Technology Assessment (HTA) programme funded trial, IVAN (inhibit VEGF in age related choroidal neovascularisation), have been presented at the annual meeting of the Association for Research in Vision and Ophthalmology and are due to be published in the journal Ophthalmology. The trial is comparing ranibizumab (Lucentis) with bevacizumab (Avastin) in 610 subjects with wet age-related macular degeneration (wet AMD) from 23 hospitals and academic institutions in the UK. (Read more...)

Full Story →